NCT04830358View on ClinicalTrials.gov

Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

August 14, 2020

Study Completion Date

February 1, 2021

Conditions
Pneumococcal Disease
Interventions
BIOLOGICAL

EuPCV15

15-valent Pneumococcal conjugate vaccine

BIOLOGICAL

Prevenar13

13-valent Pneumococcal conjugate vaccine

Trial Locations (1)

Unknown

The Catholic University of Seoul St.Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

EuBiologics Co.,Ltd

INDUSTRY

NCT04830358 - Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults | Biotech Hunter | Biotech Hunter